AUGUST 2, 2021
Top line results of SARA-INT Phase 2 study with Sarconeos (BIO101) in Sarcopenia
JULY 19, 2021
Judgment rendered on July 16, 2021 in the proceedings between Biophytis and Negma Group Ltd by the Execution Judge from the Paris Court of Justice
JULY 12, 2021
Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021
JULY 8, 2021
Biophytis Reinforces Leadership Teams with Three Senior Appointments Fullscreen Mode
JUNE 30, 2021
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study Fullscreen Mode
JUNE 30, 2021
Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021.
JUNE 18, 2021
Biophytis announces new convertible bonds financing up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million
MAY 28, 2021
Interview of Stanislas Veillet on Boursier.com
MAY 12, 2021
Biophytis Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis.
MAY 11, 2021
Results of the Combined General Meeting on May 10, 2021